Oppenheimer Analysts Give HCA Healthcare (NYSE:HCA) a $255.00 Price Target

Oppenheimer set a $255.00 price target on HCA Healthcare (NYSE:HCAGet Rating) in a research note released on Monday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for HCA Healthcare’s Q2 2022 earnings at $3.69 EPS, FY2022 earnings at $16.69 EPS, Q1 2023 earnings at $4.50 EPS, Q3 2023 earnings at $4.69 EPS and Q4 2023 earnings at $5.10 EPS.

Other analysts have also recently issued reports about the stock. Credit Suisse Group decreased their price objective on shares of HCA Healthcare from $296.00 to $260.00 and set an outperform rating on the stock in a research note on Monday, April 25th. Citigroup decreased their price target on shares of HCA Healthcare from $277.00 to $254.00 and set a buy rating on the stock in a research note on Monday, April 25th. StockNews.com cut shares of HCA Healthcare from a strong-buy rating to a buy rating in a research note on Monday, April 25th. Royal Bank of Canada reduced their price objective on shares of HCA Healthcare from $291.00 to $267.00 and set an outperform rating on the stock in a research note on Monday, April 25th. Finally, Cowen cut their target price on shares of HCA Healthcare from $265.00 to $241.00 in a report on Monday, April 25th. Five equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $257.68.

Shares of HCA opened at $177.44 on Monday. The company has a 50-day simple moving average of $210.91 and a 200-day simple moving average of $237.27. The firm has a market capitalization of $52.43 billion, a P/E ratio of 8.35, a P/E/G ratio of 1.11 and a beta of 1.61. The company has a debt-to-equity ratio of 87.46, a quick ratio of 1.24 and a current ratio of 1.43. HCA Healthcare has a 52 week low of $169.13 and a 52 week high of $279.02.

HCA Healthcare (NYSE:HCAGet Rating) last posted its quarterly earnings results on Friday, April 22nd. The company reported $4.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.27 by ($0.15). HCA Healthcare had a return on equity of 405.72% and a net margin of 11.40%. The business had revenue of $14.95 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the company earned $4.14 EPS. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, equities analysts forecast that HCA Healthcare will post 17.12 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 16th will be issued a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Wednesday, June 15th. HCA Healthcare’s payout ratio is 10.54%.

In other news, SVP Michael R. Mcalevey bought 1,110 shares of the company’s stock in a transaction dated Friday, April 29th. The stock was bought at an average cost of $218.56 per share, for a total transaction of $242,601.60. Following the transaction, the senior vice president now owns 1,110 shares of the company’s stock, valued at $242,601.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Andrea B. Smith bought 1,160 shares of the company’s stock in a transaction dated Thursday, April 28th. The stock was purchased at an average price of $213.63 per share, with a total value of $247,810.80. Following the completion of the transaction, the director now directly owns 2,239 shares in the company, valued at approximately $478,317.57. The disclosure for this purchase can be found here. Insiders have purchased a total of 91,370 shares of company stock valued at $19,373,375 in the last ninety days. 1.50% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in HCA. Dark Forest Capital Management LP acquired a new position in HCA Healthcare during the 3rd quarter worth approximately $67,000. Beacon Pointe Advisors LLC bought a new stake in HCA Healthcare during the 3rd quarter worth approximately $627,000. MML Investors Services LLC grew its holdings in HCA Healthcare by 48.9% during the 3rd quarter. MML Investors Services LLC now owns 12,548 shares of the company’s stock worth $3,046,000 after acquiring an additional 4,121 shares during the last quarter. LPL Financial LLC grew its holdings in HCA Healthcare by 21.5% during the 3rd quarter. LPL Financial LLC now owns 56,355 shares of the company’s stock worth $13,678,000 after acquiring an additional 9,958 shares during the last quarter. Finally, Verition Fund Management LLC grew its holdings in HCA Healthcare by 32.4% during the 3rd quarter. Verition Fund Management LLC now owns 3,140 shares of the company’s stock worth $762,000 after acquiring an additional 769 shares during the last quarter. Institutional investors and hedge funds own 67.87% of the company’s stock.

HCA Healthcare Company Profile (Get Rating)

HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Read More

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Oppenheimer Analysts Give HCA Healthcare (NYSE:HCA) a $255.00 Price Target

Oppenheimer set a $255.00 target price on HCA Healthcare (NYSE:HCAGet Rating) in a report published on Monday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for HCA Healthcare’s Q2 2022 earnings at $3.69 EPS, FY2022 earnings at $16.69 EPS, Q1 2023 earnings at $4.50 EPS, Q3 2023 earnings at $4.69 EPS and Q4 2023 earnings at $5.10 EPS.

Other research analysts also recently issued research reports about the stock. Truist Financial decreased their price objective on shares of HCA Healthcare from $310.00 to $250.00 and set a buy rating for the company in a research report on Monday, April 25th. StockNews.com downgraded shares of HCA Healthcare from a strong-buy rating to a buy rating in a research report on Monday, April 25th. BMO Capital Markets reduced their target price on shares of HCA Healthcare from $275.00 to $240.00 in a report on Tuesday, April 26th. Jefferies Financial Group reduced their target price on shares of HCA Healthcare from $310.00 to $275.00 in a report on Monday, April 25th. Finally, UBS Group reduced their target price on shares of HCA Healthcare from $289.00 to $241.00 and set a buy rating for the company in a report on Tuesday, April 26th. Five investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $257.68.

Shares of HCA stock opened at $177.44 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.24 and a debt-to-equity ratio of 87.46. HCA Healthcare has a 1 year low of $169.13 and a 1 year high of $279.02. The firm’s fifty day moving average price is $210.91 and its two-hundred day moving average price is $237.27. The firm has a market capitalization of $52.43 billion, a P/E ratio of 8.35, a PEG ratio of 1.11 and a beta of 1.61.

HCA Healthcare (NYSE:HCAGet Rating) last issued its quarterly earnings results on Friday, April 22nd. The company reported $4.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.27 by ($0.15). HCA Healthcare had a net margin of 11.40% and a return on equity of 405.72%. The business had revenue of $14.95 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the firm posted $4.14 earnings per share. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts forecast that HCA Healthcare will post 17.12 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 16th will be given a $0.56 dividend. This represents a $2.24 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Wednesday, June 15th. HCA Healthcare’s payout ratio is presently 10.54%.

In other HCA Healthcare news, SVP Jennifer Berres sold 2,358 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $218.87, for a total transaction of $516,095.46. Following the sale, the senior vice president now directly owns 11,392 shares of the company’s stock, valued at approximately $2,493,367.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael R. Mcalevey bought 1,110 shares of HCA Healthcare stock in a transaction on Friday, April 29th. The shares were acquired at an average cost of $218.56 per share, for a total transaction of $242,601.60. Following the completion of the acquisition, the senior vice president now directly owns 1,110 shares in the company, valued at $242,601.60. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 91,370 shares of company stock valued at $19,373,375. 1.50% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in HCA Healthcare by 7.0% during the first quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 19,882 shares of the company’s stock worth $4,983,000 after acquiring an additional 1,300 shares in the last quarter. Offit Capital Advisors LLC boosted its stake in HCA Healthcare by 33.4% during the first quarter. Offit Capital Advisors LLC now owns 2,882 shares of the company’s stock worth $722,000 after acquiring an additional 721 shares in the last quarter. J.W. Cole Advisors Inc. bought a new position in HCA Healthcare during the first quarter worth $29,000. Teachers Retirement System of The State of Kentucky boosted its stake in HCA Healthcare by 9.9% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 108,904 shares of the company’s stock worth $27,294,000 after acquiring an additional 9,843 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in HCA Healthcare by 34.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,395 shares of the company’s stock worth $5,864,000 after acquiring an additional 5,986 shares in the last quarter. 67.87% of the stock is currently owned by institutional investors.

HCA Healthcare Company Profile (Get Rating)

HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Read More

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.